AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19516160 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise intervention
Number of subjects: 3200
Study 19516160 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized women
Number of subjects: 3200
Study 19516160 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant demographics
Number of subjects: 3200
Study 16167233 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber
Number of subjects: 56
Study 16167233 — intervention group
Group type: COMPARATOR
Intervention: Control (no dietary fiber)
Number of subjects: 56
Study 11252115 — intervention group
Group type: EXPERIMENTAL
Intervention: Papanicolaou-stained smears of bronchoalveolar lavage fluid
Number of subjects: 7
Study 11252115 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects and patients with other pulmonary disorders)
Number of subjects: 7
Study 9135343 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3 mg kg‐1 (group A)
Number of subjects: 0
Study 9135343 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 4 mg kg‐1 (group B)
Number of subjects: 0
Study 9135343 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 5 mg kg‐1 (group C)
Number of subjects: 0
Study 7971302 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction technique using a kaleidoscope
Number of subjects: 100
Study 7971302 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation (control)
Number of subjects: 100
Study 3545579 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 68
Study 3545579 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 68
Study 11978335 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 9014
Study 29664001 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia started at 2 hours after onset
Number of subjects: 93
Study 29664001 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia started at 4 hours after onset
Number of subjects: 93
Study 29664001 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia started at 6 hours after onset
Number of subjects: 93
Study 29664001 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia treatment
Number of subjects: 93
Study 27484576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glutamate
Number of subjects: 824
Study 27484576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 824
Study 24233244 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity training (T(vent); 55-65 % VO(2max))
Number of subjects: 25
Study 24233244 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity training (Fat-Max; 30-40% VO(2max))
Number of subjects: 25
Study 24233244 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 25
Study 22268137 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated control of pressure support ventilation
Number of subjects: 300
Study 22268137 — intervention group
Group type: COMPARATOR
Intervention: Standardized written protocol (control group)
Number of subjects: 300
Study 20386120 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-alanine (BA, n = 14) 1.5 g + 15 g dextrose powder
Number of subjects: 44
Study 20386120 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo (PL, n = 19) 16.5 g dextrose powder
Number of subjects: 44
Study 20386120 — intervention group
Group type: COMPARATOR
Intervention: control (CON, n = 11)
Number of subjects: 44
Study 18559698 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 154
Study 18559698 — intervention group
Group type: COMPARATOR
Intervention: Intravenous abciximab
Number of subjects: 154
Study 15955378 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (clozapine, olanzapine, risperidone, quetiapine)
Number of subjects: 56
Study 12461343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan B gel
Number of subjects: 83
Study 12461343 — intervention group
Group type: COMPARATOR
Intervention: Bovine collagen
Number of subjects: 83
Study 10608577 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with sex steroids
Number of subjects: 49
Study 7791589 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated hyperoxia (FIO2 62.2%)
Number of subjects: 6
Study 7791589 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated hypoxia (FIO2 15.8%)
Number of subjects: 6
Study 7791589 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (FIO2 20.9%)
Number of subjects: 6
Study 1646341 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg AG-1749 (lansoprazole)
Number of subjects: 8
Study 1646341 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg AG-1749 (lansoprazole)
Number of subjects: 8
Study 1646341 — intervention group
Group type: COMPARATOR
Intervention: H2-receptor antagonists
Number of subjects: 8
Study 7032303 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% acyclovir ointment five times daily for 14 days
Number of subjects: 41
Study 7032303 — intervention group
Group type: COMPARATOR
Intervention: 3% vidarabine ointment five times daily for 14 days
Number of subjects: 41
Study 30807853 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg daily) with tamoxifen (10 mg twice daily from 3rd to 7th day of the cycle)
Number of subjects: 188
Study 30807853 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral vitamin B12 tablets) with tamoxifen (10 mg twice daily from 3rd to 7th day of the cycle)
Number of subjects: 188
Study 29902295 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/d)
Number of subjects: 245
Study 29902295 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib (150 mg/d)
Number of subjects: 245
Study 29902295 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/d) with ERBB mutation-positive disease
Number of subjects: 245
Study 29902295 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/d) without ERBB mutation-positive disease
Number of subjects: 245
Study 29902295 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 mutations in afatinib-treated patients
Number of subjects: 245
Study 27081739 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus reduced-dose tacrolimus (EVR + rTAC)
Number of subjects: 0
Study 27081739 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose tacrolimus (TAC)
Number of subjects: 0
Study 27081739 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus reduced-dose tacrolimus (EVR + rTAC) in hepatitis-C sub-population
Number of subjects: 0
Study 24840756 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine therapy
Number of subjects: 1433
Study 24840756 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 1433
Study 22578752 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oxytocin augmentation
Number of subjects: 536
Study 22578752 — intervention group
Group type: COMPARATOR
Intervention: Postponed oxytocin augmentation
Number of subjects: 536
Study 22578752 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative births
Number of subjects: 536
Study 22578752 — intervention group
Group type: COMPARATOR
Intervention: Both early and postponed oxytocin treatment groups
Number of subjects: 536
Study 21031585 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (n = 33)
Number of subjects: 70
Study 21031585 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 37)
Number of subjects: 70
Study 18931201 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (approximately 5-6 x 10(6) Kallikrein Inhibiting Units)
Number of subjects: 220
Study 18931201 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid (approximately 6 g)
Number of subjects: 220
Study 18931201 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 220
Study 18931201 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (CABG patients)
Number of subjects: 220
Study 18931201 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid
Number of subjects: 220
Study 18931201 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin and Tranexamic acid
Number of subjects: 220
Study 16094794 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative arts intervention
Number of subjects: 0
Study 12756096 — intervention group
Group type: COMPARATOR
Intervention: Control strip biopsy specimen used in phase 3 for difficult slides
Number of subjects: 27
Study 12756096 — intervention group
Group type: EXPERIMENTAL
Intervention: Original diagnoses by 5 pathologists in phase 1 and 3
Number of subjects: 27
Study 12756096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver evaluations by 5 pathologists in phase 2
Number of subjects: 27
Study 10951891 — intervention group
Group type: EXPERIMENTAL
Intervention: nedocromil sodium 2% ophthalmic solution b.i.d.
Number of subjects: 189
Study 9592262 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (TNZ)
Number of subjects: 52
Study 9592262 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (MNZ)
Number of subjects: 52
Study 1557575 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental regimens
Number of subjects: 0
Study 1557575 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 0
Study 3901862 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting local anaesthetic injected into the pseudoarthrosis immediately after skin closure
Number of subjects: 20
Study 3901862 — intervention group
Group type: COMPARATOR
Intervention: Placebo injected into the other side
Number of subjects: 20
Study 30797391 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Telephone Monitoring (ETM)
Number of subjects: 298
Study 30797391 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 298
Study 29954814 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 376
Study 29954814 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care chemotherapy (SOC)
Number of subjects: 376
Study 27254033 — intervention group
Group type: COMPARATOR
Intervention: Bivalent oral poliovirus vaccine
Number of subjects: 0
Study 27254033 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine
Number of subjects: 0
Study 25242048 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg daily) plus prednisone (5 mg twice a day)
Number of subjects: 2314
Study 23134881 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 portions/d of fruit and vegetables for 16 weeks
Number of subjects: 83
Study 23134881 — intervention group
Group type: COMPARATOR
Intervention: 2 portions/d of fruit and vegetables
Number of subjects: 83
Study 20974558 — intervention group
Group type: EXPERIMENTAL
Intervention: Belotero® Basic
Number of subjects: 20
Study 20974558 — intervention group
Group type: COMPARATOR
Intervention: Restylane®
Number of subjects: 20
Study 17687266 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment in bipolar patients
Number of subjects: 33
Study 17687266 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmedicated bipolar patients
Number of subjects: 33
Study 17687266 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 33
Study 15843762 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (Li+)
Number of subjects: 60
Study 15843762 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium (DVPX)
Number of subjects: 60
Study 12429243 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine 1.25% ophthalmic solution, one drop 4 times daily in the affected eye.
Number of subjects: 459
Study 12429243 — intervention group
Group type: COMPARATOR
Intervention: Neomycin-polymyxin-B-gramicidin ophthalmic solution, one drop 4 times daily in the affected eye.
Number of subjects: 459
Study 12429243 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine 1.25% ophthalmic solution
Number of subjects: 459
Study 12429243 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine 1.25% ophthalmic solution and Neomycin-polymyxin-B-gramicidin
Number of subjects: 459
Study 9428493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 168
Study 9428493 — intervention group
Group type: COMPARATOR
Intervention: Polychemotherapy (cisplatin and cyclophosphamide)
Number of subjects: 168
Study 9428493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (for patients with tumors not expressing bcl-2)
Number of subjects: 168
Study 9428493 — intervention group
Group type: EXPERIMENTAL
Intervention: Other biomarkers (p53, bcl-2, GST-pi)
Number of subjects: 168
Study 7926328 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback of the tonic stretch reflex training
Number of subjects: 8
Study 7926328 — intervention group
Group type: COMPARATOR
Intervention: No reflex training (Control)
Number of subjects: 8
Study 2803883 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 49
Study 2803883 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 49
Study 788722 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofenate
Number of subjects: 33
Study 788722 — intervention group
Group type: COMPARATOR
Intervention: Clofibate
Number of subjects: 33
Study 29495020 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based sealants (with and without fluoride)
Number of subjects: 400
Study 29495020 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment (control group)
Number of subjects: 400
Study 29495020 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealants (total retention rate)
Number of subjects: 400
Study 27854422 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster Break program
Number of subjects: 175
Study 27854422 — intervention group
Group type: COMPARATOR
Intervention: Usual-break control group
Number of subjects: 175
Study 27854422 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-based computer-prompt intervention
Number of subjects: 175
Study 24710470 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 102
Study 24710470 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 102
Study 22492518 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg, twice daily
Number of subjects: 18113
Study 22492518 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg, twice daily
Number of subjects: 18113
Study 22492518 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (target INR 2-3)
Number of subjects: 18113
Study 20424424 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (50 microg/kg/day, n = 45)
Number of subjects: 88
Study 20424424 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 43)
Number of subjects: 88
Study 18586683 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (1.0, 2.0, or 3.0 microg/kg/hr) + phenprocoumon or acenocoumarol
Number of subjects: 0
Study 18586683 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K-antagonist alone
Number of subjects: 0
Study 18586683 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing by immunologic and chromogenic assays
Number of subjects: 0
Study 18586683 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban treatment
Number of subjects: 0
Study 16103383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg) and sufentanil (5 microg)
Number of subjects: 55
Study 16103383 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural infusion of bupivacaine (0.25%) and fentanyl (2 microg/mL)
Number of subjects: 55
Study 11839141 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim‐sulfamethoxazole (TMP‐SMZ)
Number of subjects: 842
Study 10443606 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg/kg epsilon‐ACA followed by an infusion of 12.5 mg x kg(‐1) x h(‐1)
Number of subjects: 74
Study 10443606 — intervention group
Group type: COMPARATOR
Intervention: Equivalent volume of saline (control)
Number of subjects: 74
Study 7821198 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental allergen provocation with 250 PNU in 5 ml 0.9% NaCl solution of birch or grass pollen
Number of subjects: 10
Study 7821198 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental allergen provocation
Number of subjects: 10
Study 7821198 — intervention group
Group type: COMPARATOR
Intervention: Control segment (saline instillation)
Number of subjects: 10
Study 1974942 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding at one breast
Number of subjects: 12
Study 1974942 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding at two breasts
Number of subjects: 12
Study 1974942 — intervention group
Group type: COMPARATOR
Intervention: Both feeding patterns
Number of subjects: 12
Study 111322 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotepa
Number of subjects: 215
Study 111322 — intervention group
Group type: COMPARATOR
Intervention: VM‐26
Number of subjects: 215
Study 111322 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 215
Study 6761088 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg clotrimazole vaginal tablets
Number of subjects: 111
Study 6761088 — intervention group
Group type: COMPARATOR
Intervention: 150 mg econazole vaginal ovules
Number of subjects: 111
Study 30006020 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation electronic cigarettes (ECIGs) with 0 or 18 ng/ml nicotine, used ad libitum for two weeks.
Number of subjects: 25
Study 30006020 — intervention group
Group type: COMPARATOR
Intervention: Placebo electronic cigarettes (ECIGs), used ad libitum for two weeks.
Number of subjects: 25
Study 30257752 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led pre-exposure prophylaxis (PrEP) model
Number of subjects: 8000
Study 26749533 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes (high, low, and zero nicotine products)
Number of subjects: 145
Study 26749533 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes (for smokers with elevated BP)
Number of subjects: 145
Study 26749533 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes (for continuous smoking phenotype)
Number of subjects: 145
Study 24816809 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel plus bivalirudin
Number of subjects: 548
Study 24816809 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel plus heparin
Number of subjects: 548
Study 22070672 — intervention group
Group type: EXPERIMENTAL
Intervention: Analogy instruction
Number of subjects: 40
Study 22070672 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit instruction
Number of subjects: 40
Study 22070672 — intervention group
Group type: COMPARATOR
Intervention: Control condition (habitual pitch variation)
Number of subjects: 40
Study 20518225 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly massage treatments at work for a four week period
Number of subjects: 28
Study 20518225 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 28
Study 17505694 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training associated with BiPAP (physical training+B)
Number of subjects: 18
Study 17505694 — intervention group
Group type: COMPARATOR
Intervention: Physical training
Number of subjects: 18
Study 14988337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adrenaline (epinephrine)
Number of subjects: 21
Study 14988337 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume resuscitation with normal saline
Number of subjects: 21
Study 14988337 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 21
Study 12557618 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-induction group (midazolam 3 mg, alfentanil 0.5 mg, atropine 0.5 mg, propofol)
Number of subjects: 80
Study 12557618 — intervention group
Group type: COMPARATOR
Intervention: Control group (alfentanil 0.5 mg, atropine 0.5 mg, propofol)
Number of subjects: 80
Study 9829442 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous 17beta-estradiol gel (1.5 mg/d)
Number of subjects: 54
Study 9829442 — intervention group
Group type: COMPARATOR
Intervention: Transdermal 17beta-estradiol patch (50 microg/d)
Number of subjects: 54
Study 9829442 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol valerate (2 mg/d)
Number of subjects: 54
Study 7911863 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol preadsorbed onto activated charcoal (100 mg metoprolol tartrate/120 mg charcoal)
Number of subjects: 2
Study 7911863 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol preadsorbed onto activated charcoal (10 mg pindolol/20 mg charcoal)
Number of subjects: 2
Study 7911863 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol control (capsule containing the drug only)
Number of subjects: 2
Study 7911863 — intervention group
Group type: COMPARATOR
Intervention: Pindolol control (conventional tablet)
Number of subjects: 2
Study 2686934 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine plus succinylcholine (2 mg/kg)
Number of subjects: 20
Study 2686934 — intervention group
Group type: COMPARATOR
Intervention: Atropine alone (20 micrograms/kg)
Number of subjects: 20
Study 785952 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (1-acetamide-2-pyrrolidone)
Number of subjects: 18
Study 785952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31392517 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 500 mg daily for 2-6 weeks
Number of subjects: 70
Study 31392517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 27998241 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Group (WBVG)
Number of subjects: 38
Study 27998241 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent Training Group (MTG)
Number of subjects: 38
Study 27998241 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 38
Study 26227099 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa 150 μg (therapeutic dose)
Number of subjects: 0
Study 26227099 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa 240 μg (supratherapeutic dose)
Number of subjects: 0
Study 26227099 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 0
Study 26227099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0